Link Fund Solutions (LFS) has agreed to sell 'a significant portion' of Woodford's stricken LF Equity Income fund's holdings to US firm Acacia Research Corporation for up to £223.9m. The deal packages up 19 healthcare assets held by Neil Woodford's former fund, which comprise both listed and unlisted stocks including Theravance Biopharma, Oxford Nanopore and Rutherford Health. LFS confirmed the deal to investors on Friday (5 June), after reports emerged earlier in the week a deal was close. It is more than a 50% writedown to the values LFS had reportedly been close to securing from a ...
To continue reading this article...
Join International Investment
Signup and gain exclusive members-only insights
Join International Investment today
Unlock members-only benefits:
- Unlimited access to real-time news, industry insights, video features and market intelligence
- Stay ahead of the curve with spotlights on international financial centres, regional trends international advice and global industry leaders
- Receive breaking news stories straight to your inbox in the daily newsletters
- Hear the latest cross jurisdictional developments in wealth planning, tax, regulation, investing, retirement and protection
- Members-only access to the Editor’s weekly news roundup newsletter
- Members-only access to analysis via our exclusive industry polls
- Be the first to hear about our events and awards programmes
